Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 Slide Shows
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
CES 2010 Coverage 

Follow Us
RTTNews on Twitter RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

Font Down Font Up

Merck, Schering-Plough Proposed Merger Gets U.S., Canadian And Swiss Regulatory Approval
10/29/2009 9:02 PM  ET
RELATED NEWS
Merck's Follicle Stimulent Elonva Granted European Commission Approval - Update
Merck & Co Gets European Commission Approval For ELONVA - Quick Facts
Merck Loses Temodar Patent Infringement Suit Against Teva; To Appeal Against Ruling - Update
Merck Says Court Ruled Against Merck In Temodar Patent Lawsuit - Quick Facts
Merck Set New High For Year Wednesday

Trade MRK now with
TOP MARKET NEWS
Micron Technology Agrees To Buy Privately-held Numonyx For US$1.27 Bln Stock - Update
NZ Dollar Declines From New Multi-day Highs Against Most Majors
Australian Dollar Eases From Multi-day Highs Against Euro And Yen
EOG Resources Q4 Profit Down 13%; Raises Quarterly Dividend - Update
Yen Off Fresh Multi-day Lows Against Majors
(RTTNews) -  Thursday, Pharmaceutical giant Merck & Co. Inc.'s (MRK: News ) proposed $41 billion cash-and-stock acquisition deal of rival Schering-Plough Corp. (SGP: News ) was approved by the U.S. Federal Trade Commission, the Swiss Competition Commission and the Canadian Competition Bureau.

The three regulates mergers within their respective countries to avoid anticompetitive effects arising from conglomerate mergers within their countries.

Earlier on October 23, the proposed merger of Merck and Schering-Plough received anticompetitive clearance from the European Commission regulators.

Since Merck and Schering sell their products to consumers in the U.S., Canada, and also in European Union exceeding given thresholds, it is mandatory for the companies to get approval from these regulators. The regulators were concerned that the tie-up would significantly impede effective competition, particularly in the field of products for asthma and allergic rhinitis.

However, the companies said today that the FTC and the Canadian Competition Bureau terminated the waiting period and cleared the pending merger.

Commenting on the approvals, chairman, president and chief executive officer of Merck, Richard Clark said, "Clearances from the FTC, the Swiss Competition Commission and the Canadian Competition Bureau mark significant steps in the completion of our merger with Schering-Plough. As we work with regulators on the remaining approvals necessary for the close, we stand ready to serve patient needs as a new global healthcare leader."

The transaction, however, still remains subject to approval from other regulators, including China and Mexico.
In March, Merck agreed to buy Schering-Plough in a $41.1 billion stock and cash transaction. The deal terms provides Schering-Plough shareholders with 0.5767 shares of Merck and $10.50 in cash, and the aggregate consideration will comprise a combination of about 56% stock and 44% cash. Earlier in the month, both Merck and Schering-Plough shareholders approved the merger.

The proposed merger got shareholders approval with 99% majority voting on July 8. On the same day, Schering-Plough also approved the takeover deal.

Merck is research-driven pharmaceutical company active in pharmaceuticals and vaccines, while Schering-Plough is a science-based healthcare company, active in human prescription pharmaceuticals, animal health and over-the-counter, consumer healthcare.

The estimated $41 billion cash-and-stock deal between Merck and Schering-Plough has been structured as a reverse merger. Under the reverse merger, Merck would technically become a wholly owned subsidiary of Schering even though it is Merck, which is acquiring Schering. The combined company will be headed by Merck chief executive officer Richard Clark.

To receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print           Follow Us RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

     
  

More Top Stories-US

34  Micron Technology Agrees To Buy Privately-held Numonyx For US$1.27 Bln Stock - Update
33  EOG Resources Q4 Profit Down 13%; Raises Quarterly Dividend - Update
32  UDR Q4 FFO Declines; Guides FY10
31  Baidu Q4 Profit Up 48.2%; Guides Q1 Revenue Above Estimates
30  IMS Health Profit Declines 27%
29  CareFusion Q2 Profit Declines; Revises Up FY10 View - Update
28  Cerner Earnings Decline, Top Estimates
27  Disney Profit Tops Estimate
26  XL Capital Posts Narrower Loss In Q4 - Update
25  Obama Calls For Give And Take With GOP
24  Wall Street Sees Strong Gains Amid Prospective Greece Bailout
23  Reports: Germany Yet To Decide On Possible Aid Package To Greece
22  Obama Meets With House And Senate Leaders In Effort To Boost Bipartisanship
21  Opel/Vauxhall Unveils €11 Bln Investment Plan; To Cut 8,300 Jobs
20  S&P Trims Outlook On BofA, Citigroup; Affirms Ratings - Update

 

Copyright © 2010 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service| How To Use RTTNews.com| Advertise| Privacy| Buy Content | RSS